SALT LAKE CITY, April 20, 2021 /PRNewswire/
-- Co-Diagnostics, Inc. (Nasdaq: CODX), a
molecular diagnostics company with a unique, patented platform for
the development of diagnostic tests, announced today that its Logix
Smart™ COVID-19 Test Kit was used by Australian researchers to
demonstrate rapidly deployable mobile molecular diagnostics support
for remote locations, with the peer-reviewed results published in
the Journal of Medical Microbiology.
The test demonstrated an analytical sensitivity of 1010 viral
copies/ml, comparable to others used across W. Australia
The study was performed using readily available open-source
equipment and materials that could be successfully operated in
regional clinical laboratories, many of which are not currently
equipped for molecular diagnostics. When tested on clinical
samples, the sensitivity and specificity of the Company's test
showed complete concordance with the comparison assay used in the
study. The researchers also demonstrated an analytical sensitivity
of 1010 viral copies per milliliter, which they found to be
comparable to other tests used across Western Australia.
Dwight Egan, Chief Executive
Officer of Co-Diagnostics, remarked, "We believe the results of
this independent peer-reviewed paper further establishes the
robustness, versatility, and quality of our Logix Smart COVID-19
diagnostic. Strong sales of our COVID-19 products continue
domestically and abroad, illustrating the success of our business
model as part of our continued commitment to making affordable
molecular diagnostics available in settings ranging from
high-throughput CLIA labs to remote locations across the world.
Co-Diagnostics believes this study demonstrates that commitment, in
addition to the advantages and adaptability of our CoPrimer™
technology."
The Journal of Medical Microbiology paper can be found
here.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah
corporation, is a molecular diagnostics company that develops,
manufactures and markets a new, state-of-the-art diagnostics
technology. The Company's technology is utilized for tests that are
designed using the detection and/or analysis of nucleic acid
molecules (DNA or RNA). The Company also uses its proprietary
technology to design specific tests to locate genetic markers for
use in industries other than infectious disease and license the use
of those tests to specific customers.
Forward-Looking Statements:
This press release
contains forward-looking statements. Forward-looking statements can
be identified by words such as "believes," "expects," "estimates,"
"intends," "may," "plans," "will" and similar expressions, or the
negative of these words. Such forward-looking statements are based
on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and conditions.
Forward-looking statements in this release include statements
regarding the (i) use of funding proceeds, (ii) expansion of
product distribution, (iii) acceleration of initiatives in liquid
biopsy and SNP detection, (iv) use of the Company's liquid biopsy
tests by laboratories, (v) capital resources and runway needed to
advance the Company's products and markets, (vi) increased sales in
the near-term, (vii) flexibility in managing the Company's balance
sheet, (viii) anticipation of business expansion, and (ix) benefits
in research and worldwide accessibility of the CoPrimer technology
and its cost-saving and scientific advantages. Forward-looking
statements are subject to inherent uncertainties, risks and changes
in circumstances. Actual results may differ materially from
those contemplated or anticipated by such forward-looking
statements. Readers of this press release are cautioned not to rely
on any forward-looking statements. Any forward-looking statement
made by the Company in this press release is based only on
information currently available to the Company and speaks only as
of the date on which it is made. The Company does not undertake any
obligation to update any forward-looking statement relating to
matters discussed in this press release, except as may be required
by applicable securities laws.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/co-diagnostics-inc-test-performance-demonstrated-by-australian-researchers-in-peer-reviewed-publication-301272608.html
SOURCE Co-Diagnostics